Altered Cholinergic Innervation in De Novo Parkinson's Disease with and without Cognitive Impairment

被引:53
作者
van der Zee, Sygrid [1 ,2 ]
Kanel, Prabesh [3 ,4 ]
Gerritsen, Marleen J. J. [1 ,2 ]
Boertien, Jeffrey M. [1 ]
Slomp, Anne C. [1 ,2 ]
Muller, Martijn L. T. M. [3 ,4 ]
Bohnen, Nicolaas, I [3 ,4 ,5 ,6 ,7 ,8 ]
Spikman, Jacoba M. [1 ,2 ]
van Laar, Teus [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr, Dept Neurol, Div Clin Neuropsychol, Groningen, Netherlands
[3] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Morris K Udall Ctr Excellence Parkinsons Dis Res, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Neurol, Ann Arbor, MI USA
[6] Vet Adm Ann Arbor Healthcare Syst, Neurol Serv, Ann Arbor, MI USA
[7] Vet Adm Ann Arbor Healthcare Syst, GRECC, Ann Arbor, MI USA
[8] Univ Michigan, Parkinsons Fdn Ctr Excellent, Ann Arbor, MI USA
关键词
Parkinson's disease; cognition; acetylcholine; positron emission tomography imaging; DIAGNOSTIC-CRITERIA; FRONTAL-CORTEX; DEMENTIA; DENERVATION; DEFICITS; PLACEBO; SCALE;
D O I
10.1002/mds.28913
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Altered cholinergic innervation plays a putative role in cognitive impairment in Parkinson's disease (PD) at least in advanced stages. Identification of the relationship between cognitive impairment and cholinergic innervation early in the disease will provide better insight into disease prognosis and possible early intervention. Objective The aim was to assess regional cholinergic innervation status in de novo patients with PD, with and without cognitive impairment. Methods Fifty-seven newly diagnosed, treatment-naive, PD patients (32 men, mean age 64.6 +/- 8.2 years) and 10 healthy controls (5 men, mean age 54.6 +/- 6.0 years) were included. All participants underwent cholinergic [F-18]fluoroethoxybenzovesamicol positron emission tomography and detailed neuropsychological assessment. PD patients were classified as either cognitively normal (PD-NC) or mild cognitive impairment (PD-MCI). Whole brain voxel-based group comparisons were performed. Results Results show bidirectional cholinergic innervation changes in PD. Both PD-NC and PD-MCI groups showed significant cortical cholinergic denervation compared to controls (P < 0.05, false discovery rate corrected), primarily in the posterior cortical regions. Higher-than-normal binding was most prominent in PD-NC in both cortical and subcortical regions, including the cerebellum, cingulate cortex, putamen, gyrus rectus, hippocampus, and amygdala. Conclusion Altered cholinergic innervation is already present in de novo patients with PD. Posterior cortical cholinergic losses were present in all patients independent of cognitive status. Higher-than-normal binding in cerebellar, frontal, and subcortical regions in cognitively intact patients may reflect compensatory cholinergic upregulation in early-stage PD. Limited or failing cholinergic upregulation may play an important role in early, clinically evident cognitive impairment in PD. (c) 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
引用
收藏
页码:713 / 723
页数:11
相关论文
共 48 条
[11]   The cholinergic system and Parkinson disease [J].
Bohnen, Nicolaas I. ;
Albin, Roger L. .
BEHAVIOURAL BRAIN RESEARCH, 2011, 221 (02) :564-573
[12]   A Major External Source of Cholinergic Innervation of the Striatum and Nucleus Accumbens Originates in the Brainstem [J].
Dautan, Daniel ;
Huerta-Ocampo, Icnelia ;
Witten, Ilana B. ;
Deisseroth, Karl ;
Bolam, J. Paul ;
Gerdjikov, Todor ;
Mena-Segovia, Juan .
JOURNAL OF NEUROSCIENCE, 2014, 34 (13) :4509-4518
[13]   Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment [J].
DeKosky, ST ;
Ikonomovic, MD ;
Styren, SD ;
Beckett, L ;
Wisniewski, S ;
Bennett, DA ;
Cochran, EJ ;
Kordower, JH ;
Mufson, EJ .
ANNALS OF NEUROLOGY, 2002, 51 (02) :145-155
[14]   Cognitive function in the early phase of Parkinson's disease, a five-year follow-up [J].
Domellof, M. E. ;
Ekman, U. ;
Forsgren, L. ;
Elgh, E. .
ACTA NEUROLOGICA SCANDINAVICA, 2015, 132 (02) :79-88
[15]   Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes [J].
Gilman, S. ;
Koeppe, R. A. ;
Nan, B. ;
Wang, C-N. ;
Wang, X. ;
Junck, L. ;
Chervin, R. D. ;
Consens, F. ;
Bhaumik, A. .
NEUROLOGY, 2010, 74 (18) :1416-1423
[16]   Diagnosing PD-MCI by MDS Task Force Criteria: How Many and Which Neuropsychological Tests? [J].
Goldman, Jennifer G. ;
Holden, Samantha ;
Ouyang, Bichun ;
Bernard, Bryan ;
Goetz, Christopher G. ;
Stebbins, Glenn T. .
MOVEMENT DISORDERS, 2015, 30 (03) :402-406
[17]   A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease [J].
Grace, J. ;
Amick, M. M. ;
Friedman, J. H. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (01) :18-23
[18]   The neurobiological basis of cognitive impairment in Parkinson's disease [J].
Halliday, Glenda M. ;
Leverenz, James B. ;
Schneider, Jay S. ;
Adler, Charles H. .
MOVEMENT DISORDERS, 2014, 29 (05) :634-650
[19]   Dementia in Parkinson disease - Functional imaging of cholinergic and dopaminergic pathways [J].
Hilker, R ;
Thomas, AV ;
Klein, JC ;
Weisenbach, S ;
Kalbe, E ;
Burghaus, L ;
Jacobs, AH ;
Herholz, K ;
Heiss, WD .
NEUROLOGY, 2005, 65 (11) :1716-1722
[20]   Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease [J].
Ikonomovic, Milos D. ;
Abrahamson, Eric E. ;
Isanski, Barbara A. ;
Wuu, Joanne ;
Mufson, Elliott J. ;
DeKosky, Steven T. .
ARCHIVES OF NEUROLOGY, 2007, 64 (09) :1312-1317